Exenatide and Semaglutide are both GLP-1 receptor agonists, a class of drugs primarily used for metabolic health, including Type 2 Diabetes and obesity. Based on the studies indexed here, Exenatide shows potential beyond metabolism, with a comprehensive review suggesting its utility for psychiatric disorders. Semaglutide, in a network meta-analysis of 67,769 patients, demonstrated a 26% reduction in cardiovascular mortality in T2DM patients. Both peptides are being investigated for their broader benefits, moving beyond primary weight loss to encompass a wider spectrum of metabolic and organ-specific outcomes.
| Exenatide | Semaglutide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist |
| Studies in corpus | 18 | 691 |
| Highest evidence tier | meta analysis | meta analysis |
| Evidence tier mix | rct · 4 meta analysis · 2 other · 5 cohort · 1 review · 1 | rct · 67 meta analysis · 9 review · 23 in vitro · 4 cohort · 16 preclinical animal · 4 case report · 3 case series · 3 other · 26 |
| Studies with explicit sample size | 5 | 42 |
| Head-to-head studies in corpus | 4 | |
Studies in our corpus that mention both Exenatide and Semaglutide — the gold-standard direct comparison evidence.
This comprehensive meta-analysis suggests that current evidence does not consistently support GLP-1RAs as an effective treatment for motor or non-motor symptoms in Parkinson's disease. While the modest improvement in quality of life is a notable finding, it…
This analysis highlights a critical shift in the clinical research paradigm for GLP-1 agonists in obesity, moving beyond primary weight loss to encompass a wider spectrum of metabolic and organ-specific benefits. Clinicians and researchers should recognize …
Dulaglutide reduced stroke risk by 23% (RR: 0.77) and semaglutide lowered cardiovascular mortality by 26% (RR: 0.74) in T2DM patients, a network meta-analysis of 67,769 found.
This study's methodology establishes a crucial framework for comparing two significant obesity interventions—GLP-1 RAs and bariatric surgery—in the context of IBD management. For clinicians and patients navigating obesity alongside IBD, understanding which …
No direct head-to-head trials in our corpus. Indirect comparison only. While both are GLP-1 receptor agonists, their specific efficacy outcomes in direct comparisons are limited in our corpus. A network meta-analysis found that semaglutide lowered cardiovascular mortality by 26% in T2DM patients. Exenatide's impact on cardiac biomarkers like NT-proBNP and hs-cTnT is being explored to refine cardiovascular risk stratification in Type 2 Diabetes. One study also notes the investigation of Exenatide Once Weekly versus Liraglutide Daily for Type 2 Diabetes, suggesting different dosing frequencies within the GLP-1 RA class. Semaglutide also has an oral formulation, with oral semaglutide 25 mg achieving exposure similar to SC 2.4 mg and leading to greater weight loss in simulated studies. The corpus contains 20 studies on Exenatide and 729 on Semaglutide, indicating a substantially larger body of research for Semaglutide in our indexed studies.
Looking for vendor-level purity, endotoxin, and HPLC data on Exenatide or Semaglutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.